Pharmacy

Olympics     2012     partner, GlaxoSmithKline, has signed a long- term agreement with the World Anti-Doping Agency  (WADA) to create early detection method for medicines with performance- enhancing potential in sport. Under the agreement, GSK scientists would specifically identify substances with a probable or high risk of abuse in sport.

These scientists would seek similarity to the pharmacological characteristics of existing performance-enhancing substances and analyses their reaction in the human body. This would include stimulatory effects or improved physical endurance.

The historic partnership, which was officially ratified in London on June 23, will see GSK supply WADA with confidential information about medicines in early stage development that will be abused by athletes once they are licenced for appropriate patient use. John Fahey, President, WADA, said, "Our work with the pharmaceutical industry is critical to staying one step ahead of the dopers, who have an ever increasing level of scientific expertise. We are delighted to be entering into this partnership with GSK as it will play a significant role in helping WADA achieve its mission of a doping-free sporting culture."